First online edition
Arab Pharma Manufacturers’ Expo 2020
During the pandemic situation, healthcare manufacturing has remained a top priority all around the world in terms of continuous investments and expansions at the pharma manufacturing facilities across the world.
The frist online edition of the 3rd ARAB PHARMA MANUFACTURERS’ EXPO 2020 – an international exhibition on complete pharma manufacturing focusing Arabic countries in Middle East & North Africa (MENA) region has drawn attention of buyers and trade professionals attended from more than 20 countries to virtually meet the exhibiting companies for business networking and to attend the Technology Presentations.
Keeping in mind the health advisories by the Government due to the pandemic, the online Exhibition integrated all the basic essential features to the exhibiting companies to generate optimum output in terms of display and communication while participation in a highly cost effective manner.
More than 45 live Technology Presentations addressing the latest trends and current practices of pharma manufacturing technologies by the exhibiting companies spanning over 6 days as concurrent event alongside the online exhibition had remained highly resourceful for pharma manufacturing fraternity to acquire the technology based information.
Overall, the exhibitors have well appreciated the novel concept of the online exhibition, as it applies all the latest technical aspects to offer the optimum business networking domain bypassing all the limitations.
Outstanding benefits of the exhibition are the acceleration of an instant business connectivity, global exposure without any geographical barriers, ease of accessibilities and business networking through mobile, laptop or computer, longer exhibit hours, live chat to engage with prospective suppliers, live technology presentations, real-time experience with negligible investment, options of affordable packages for cost effective participation, and, most importantly, bypass of several other associated costs and time.
Fight against COVID-19
Technology for gene-based vaccines
The COVID-19 pandemic has prompted a breakthrough in gene-based vaccines. Currently, the only established process for transporting mRNA vaccines into the human cell is encapsulation by means of lipid nanoparticles (LNP). Without this protection, the mRNA with the blueprint for stimulating the immune system could not reach the right site of action in the body. Within seconds it would degrade in the bloodstream and make the vaccine ineffective.
“Coping with the pandemic depends largely on the availability of effective vaccines,” says Christian Kullmann, chairman of Evonik’s executive board. “The fact that the supply of vaccines is imminent is an outstanding achievement of the pharmaceutical and biotech industry, which we support with highly specialized applications from formulation development to production”. The innovation growth field Healthcare Solutions in the life-science division Nutrition & Care has been growing strongly ever since its formation. For decades, the company has been a leader in the field of drug delivery technologies, which includes lipid nanoparticles. “We are now consistently expanding this position as a solutions provider and integrated development partner.”
Evonik believes that its drug delivery technologies and services have great potential for above-average growth in vaccines as well as cell and gene therapies. Gene therapies, including those involving mRNA active ingredients and the use of lipid nanoparticles, open up the potential for the Health Care business line to generate revenues in the clear triple-digit millions within the next years.
The COVID-19 pandemic has now greatly accelerated the growth of innovative therapeutic approaches. In addition to the vaccines against COVID-19, which are close to approval, the head of Evonik’s Health Care business line, Thomas Riermeier, sees numerous other areas of application on the verge of breakthrough, and Evonik is helping to develop them. “Innovative vaccines against influenza, malaria or HIV are just as conceivable as promising approaches for cancer immunotherapy, the treatment of hereditary diseases or defective genes.” A major step in gene editing is expected within the next five years.
Evonik has supported various COVID-19 vaccine projects, from development to the production of clinical samples. As one of the integrated development partners for gene-based therapies, Evonik has been involved in over 100 projects in the past years, within various application fields.
“The higher efficacy as well as the significantly shorter development times are advantages of gene-based drug products that are currently becoming particularly apparent. The dynamics of the market show a paradigm shift in the way the industry will develop and produce drugs in the future,” says Riermeier. Evonik intends to further expand its position as an integrated solutions provider in this market. This includes the marketing of special pharmaceutical excipients such as lipids, the development of formulations, i.e. the combination of excipients and active ingredients, as well as the production of clinical test samples, and the production of commercial quantities. The expansion of clinical production capacities is also being planned, as is the expansion of manufacturing capacities for commercial quantities.
Evonik recognized the potential of gene-based therapeutic approaches early on. For customers worldwide, the specialty chemicals company develops and formulates lipid nanoparticles in Burnaby (BC, Canada) and operates a plant for the production of commercial quantities in Birmingham (AL, USA).
“With the acquisition of Burnaby-based Transferra Nanosciences, we deliberately invested in this promising technology in 2016,” explains Riermeier. With the acquisition of Wilshire Technologies, a US manufacturer of natural excipients for the pharmaceutical industry, the portfolio was further expanded in early 2020.
Evonik has signed an agreement to acquire the LACTEL® business of biodegradable polymers from DURECT Corporation for USD 15m. The transaction is expected to close by Q1 2021 pending the satisfaction of certain customary closing conditions. An offer will be extended to each of the 15 employees of DURECT located in Birmingham, Alabama, which are associated with the LACTEL® business to transition to the Evonik.
“The acquisition of the Lactel® business will strengthen both our innovation growth field Healthcare Solutions and Evonik’s position as a globally leading CDMO for drug delivery solutions”, says Johann-Caspar Gammelin, Head of the Nutrition & Care Division of Evonik. The acquisition marks a consequential step in the growth agenda of the life-science division Nutrition & Care. The LACTEL® business will benefit from fast-growing markets such as advanced drug delivery, biomaterials for tissue engineering, and the 3D printing of implantable medical devices.
“It has been a pleasure working with the highly motivated and talented LACTEL® team. We have confidence that Evonik will apply its resources and commitment to excellence to enable the product line and supporting team members to thrive,” says James E. Brown, President and Chief Executive Officer of DURECT Corporation. With Evonik’s global reach, existing and new customers will benefit from tapping into Health Care’s twelve global laboratories staffed with formulation, application and regulatory experts to assist in bringing their products faster to the market.
“The integration of the LACTEL® business into Evonik’s market-leading portfolio of functional excipients, biomaterials and integrated CDMO services will strengthen our position as a preferred development partner and solutions provider for pharmaceutical and medical device customers,” says Thomas Riermeier, Head of the Health Care business line. “By welcoming LACTEL® and members of their team into the Evonik family, we look forward to providing customers with even greater platform versatility as well as other value-adding services.”
Poly(lactide-co-glycolide) polymers are widely used as a functional excipient to control the release of parenteral drug products. They are also utilized to control the biodegradation of implantable medical devices across various orthopedic, cardiovascular, wound healing and other applications.